Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression - PubMed (original) (raw)
Clinical Trial
. 1999 Dec 1;163(11):6292-300.
Affiliations
- PMID: 10570323
Clinical Trial
Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
K H Lee et al. J Immunol. 1999.
Abstract
Although in vitro sensitization assays have shown increased melanoma Ag (MA)-specific CTL reactivity after vaccination with MA peptides, clinical responses have been uncommon. This paradox questions whether data obtained from the in vitro stimulation and expansion of T cells lead to an overestimation of the immune response to vaccines. Using HLA/peptide tetramer (tHLA), we enumerated MA-specific T cell precursor frequency (TCPF) directly in PBMC from 23 melanoma patients vaccinated with gp100:209-217(210M) (g209-2M) peptide. Vaccine-specific TCPF was higher in postvaccination PBMC from seven of seven patients treated with peptide alone and four of five patients treated with peptide plus IL-12 (range of postvaccination TCPF, 0.2-2.4% and 0.2-2.5%, respectively). The increased TCPF correlated with enhanced susceptibility to in vitro stimulation with the relevant epitope. Paradoxically, no increase in postvaccination TCPF was observed in most patients who had been concomitantly treated with IL-2 (1 of 11 patients; range of postvaccination TCPF, 0.02-1.0%), a combination associated with enhanced rates of tumor regression. The lack of increase in TCPF seen in these patients corresponded to inability to elicit expansion of vaccine-specific T cells in culture. This study shows that a peptide-based vaccine can effectively generate a quantifiable T cell-specific immune response in the PBMC of cancer patients, though such a response does not associate with a clinically evident regression of metastatic melanoma.
Similar articles
- Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA. Pass HA, et al. Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23. Cancer J Sci Am. 1998. PMID: 9815296 Clinical Trial. - T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA. Dudley ME, et al. Cancer J. 2000 Mar-Apr;6(2):69-77. Cancer J. 2000. PMID: 11069222 - Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
Smith JW 2nd, Walker EB, Fox BA, Haley D, Wisner KP, Doran T, Fisher B, Justice L, Wood W, Vetto J, Maecker H, Dols A, Meijer S, Hu HM, Romero P, Alvord WG, Urba WJ. Smith JW 2nd, et al. J Clin Oncol. 2003 Apr 15;21(8):1562-73. doi: 10.1200/JCO.2003.09.020. J Clin Oncol. 2003. PMID: 12697882 Clinical Trial. - Melanoma vaccines: the paradox of T cell activation without clinical response.
Nielsen MB, Marincola FM. Nielsen MB, et al. Cancer Chemother Pharmacol. 2000;46 Suppl:S62-6. doi: 10.1007/pl00014052. Cancer Chemother Pharmacol. 2000. PMID: 10950150 Review. - Melanoma vaccines.
Yang JC. Yang JC. Cancer J. 2011 Sep-Oct;17(5):277-82. doi: 10.1097/PPO.0b013e3182325f72. Cancer J. 2011. PMID: 21952276 Review.
Cited by
- A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma.
Tan TJ, Ang WXG, Wang WW, Chong HS, Tan SH, Cheong R, Chia JW, Syn NL, Shuen WH, Ba R, Kaliaperumal N, Au B, Hopkins R, Li X, Tan AC, Seet AOL, Connolly JE, Arkachaisri T, Chew V, Lajam ABM, Guo D, Chew MZW, Wasser M, Kumar P, Albani S, Toh HC. Tan TJ, et al. Nat Commun. 2022 Oct 28;13(1):6453. doi: 10.1038/s41467-022-33834-4. Nat Commun. 2022. PMID: 36307410 Free PMC article. Clinical Trial. - Design of Personalized Neoantigen RNA Vaccines Against Cancer Based on Next-Generation Sequencing Data.
Alburquerque-González B, López-Abellán MD, Luengo-Gil G, Montoro-García S, Conesa-Zamora P. Alburquerque-González B, et al. Methods Mol Biol. 2022;2547:165-185. doi: 10.1007/978-1-0716-2573-6_7. Methods Mol Biol. 2022. PMID: 36068464 - In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines.
Lőrincz O, Tóth J, Molnár L, Miklós I, Pántya K, Megyesi M, Somogyi E, Csiszovszki Z, Tőke ER. Lőrincz O, et al. Cells. 2021 Nov 5;10(11):3048. doi: 10.3390/cells10113048. Cells. 2021. PMID: 34831269 Free PMC article. - Cancer immune resistance: can theories converge?
Lu R, Turan T, Samayoa J, Marincola FM. Lu R, et al. Emerg Top Life Sci. 2017 Dec 12;1(5):411-419. doi: 10.1042/ETLS20170060. Emerg Top Life Sci. 2017. PMID: 33525800 Free PMC article. - The Effect of Different Immunization Cycles of a Recombinant Mucin1-Maltose-Binding Protein Vaccine on T Cell Responses to B16-MUC1 Melanoma in Mice.
Zhou H, Zhang Z, Liu G, Jiang M, Wang J, Liu Y, Tai G. Zhou H, et al. Int J Mol Sci. 2020 Aug 13;21(16):5810. doi: 10.3390/ijms21165810. Int J Mol Sci. 2020. PMID: 32823603 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials